Get notified of page updates
Education > XRAY > Ovarian Cancer

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Ovarian Cancer

61 through 70 of 75

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Does scalp cooling help prevent hair loss after chemotherapy?

Most relevant for: Patient undergoing chemotherapy

Hair loss is one of the most recognized and distressing side effects of some chemotherapies. Two studies looked at the use of scalp cooling therapy to help reduce hair loss after chemotherapy for early-stage breast cancer. (5/15/17) 

Update: Based on data from clinical trials, the FDA approved Dignicap scalp cooling device for treatment in patients diagnosed with solid tumors who are receiving chemotherapy. 

Read More

Relevance: Medium

Strength of Science: Medium-Low

View Related Clinical Trials

Study : Angelina Jolie spoke out on BRCA testing: Did genetic testing increase?

Most relevant for: People interested in genetic testing for an inherited mutation

Angelina Jolie published an editorial in the New York Times in 2013 about her choice to have a double mastectomy after finding out she was positive for a BRCA1 mutation. Researchers from a recent study claim that her celebrity endorsement of BRCA testing may have missed its target audience (previvors), due to the increase in BRCA testing following publication of the editorial but a decrease in the number of mastectomies performed. However, the study failed to take into account that many women without breast cancer do not pursue mastectomy in the months following genetic testing. (1/4/17)

Read More

Relevance: Medium

Strength of Science: Medium-High

View Related Clinical Trials

Study : Removing ovaries before age 50 may increase the risk of chronic conditions for some women

Most relevant for: Women under 50 years of age who have had or are considering removing their ovaries

Removal of ovaries and fallopian tubes prevents ovarian cancer, but it may come with other health risks. Experts recommend removal of ovaries and fallopian tubes in women at high risk for ovarian cancer due to inherited mutations in BRCA or other genes linked to ovarian cancer risk. For these high-risk women the benefit of ovarian cancer prevention outweighs the risk of long-term complications. Based on a recent study, some researchers feel that for women who are not at increased risk for cancer, the risk for some chronic conditions is too high to consider removal of both ovaries. (11/1/16)

Read More

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Study : Rare mutations in PALB2, CHEK2, and ATM: how much do they increase cancer risk?

Most relevant for: People who tested positive for one of the rare variants in CHEK2, ATM or PALB2 that are covered in this study

As multi-gene panel tests become more common, people are discovering they have mutations in genes that are not understood as well as BRCA. This can make it difficult to give patients accurate assessments of their cancer risk. For example, mutations in PALB2, CHEK2, and ATM are rare, but some specific changes in these genes are even less common. The goal of this international collaboration was to better understand the cancer risks of some very rare PALB2, CHEK2, and ATM mutations. The findings are relevant only to the specific mutations covered in this paper and do not apply to all people with mutations in PALB2, CHEK2, or ATM. (9/27/16)

Read More

Relevance: Medium

Quality of Writing: High

Article : A cancer patient’s tumor is genetically profiled—how does that info help treatment?

Most relevant for: People diagnosed with advanced cancer

Jessica Wapner's Scientific American article explores the difficulties of making the vast amount of information acquired from tumor gene tests useful to patients and physicians. (9/20/16). Update: THIS INFORMATION HAS BEEN UPDATED. In late 2017, the FDA approved two separate tumor profiling tests to help guide treatment choices. The FoundationOne CDx (F1CDx) genomic test has been approved to test for 15 different targeted therapies used to treat five types of cancer, including ovarian, colorectal, lung, breast and melanoma. The FDA also approved the MSK-IMPACT and developed for use by Memorial Sloan Kettering Cancer Center (MSKCC) to scan tumor samples for 468 different cancer-associated mutations or alterations.

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Study : Do BRCA mutations affect fertility?

Most relevant for: Women with a BRCA mutation who want to become pregnant

Age affects fertility. As women age, their ovaries release eggs that are not as healthy as those released in younger women. Fewer eggs are released each menstrual cycle as women age, making it harder for older women to become pregnant. Are women with BRCA mutations less fertile? Previous research suggested that BRCA mutations might affect women's fertility as she ages. A recent study found that BRCA1 mutation carriers may have slightly lower fertility than women without the same mutation, but more research is needed before this finding is useful for medical decision-making. (5/24/16)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Study : Financial burden affects quality of life of cancer survivors

Most relevant for: People diagnosed with cancer

Cancer-related financial burden can keep survivors from getting the care that they need, yet how this burden affects mental and physical health is still unknown. A study found that almost one-third of cancer survivors report having financial burden; those most likely to be affected were under age 65, female, members of racial or ethnic minority groups, and people who lack access to adequate insurance. (5/17/16)

Read More

Relevance: Medium-High

Strength of Science: Medium-High

View Related Clinical Trials

Study : Factors that affect the ability to work in people with metastatic cancer

Most relevant for: People living with metastatic cancer

Some patients who live with metastatic cancer either want or need to continue working while coping with symptoms of their disease and treatment. A recent study that looked at over 600 people with metastatic breast, prostate, colon, or lung cancer found that about one-third of them continue working full or part time. People most likely to continue working were those undergoing hormonal treatment and those with less severe symptoms or side effects from treatment. (4/12/16)

Read More

Relevance: Medium

Quality of Writing: Medium-Low

View Related Clinical Trials

Article : New York Times report demonstrates need for genetic counseling, but doesn’t give the whole story

Most relevant for: People diagnosed with breast cancer

A New York Times report discussed how genetic testing could provide “grim data” without guidance for patients. While this is a valid concern, this report does not sufficiently emphasize certain important issues regarding genetic testing, particularly the need for genetic counseling by a health care provider with expertise in genetics before and after genetic testing. (4/5/16)

Read More

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : What are the genetics underlying 12 different cancer types?

Most relevant for: People diagnosed with cancer

As gene sequencing has become more affordable, researchers and health care providers are now looking for mutations in many genes beyond BRCA1, BRCA2 and others that are associated with known hereditary cancer syndromes. By sequencing thousands of genes rather than just one or two, researchers can better understand which inherited mutations affect cancer risk. In this study, researchers sequenced thousands of genes in patients with one of 12 cancers, including breast, and catalogued which gene mutations are most commonly found in each cancer. (03/01/16)

Read More

This Portal Sponsored By:

AstraZeneca